Carvedilol Phosphate Capsule, Extended Release
Product Images NDC 16714-228

10 FDA label images from Northstar Rxllc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 16714-228). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Carvedilol 1)

Structure (Carvedilol 1)
Chemical structure of carvedilol phosphate, showing the molecular arrangement including an indole group, ether linkages, hydroxyl group, and methoxybenzene, with associated phosphate and water components.*
FDA Label Image

Figure-1 (Carvedilol Figure1)

Figure-1 (Carvedilol Figure1)
A line graph showing percent mortality over 21 months comparing Carvedilol and placebo groups. The graph shows lower mortality for Carvedilol than placebo, with time in months on the x-axis and percent mortality on the y-axis. A statistical p-value of 0.0014 is noted on the graph.*
FDA Label Image

Figure-2 (Carvedilol Spl Figure 2)

Figure-2 (Carvedilol Spl Figure 2)
A forest plot chart depicting hazard ratios for various patient subgroups including men, women, age categories (<65, ≥65), race (non-black, black), diabetic status, ischemic versus nonischemic conditions, heart rate groups, systolic blood pressure categories, and spironolactone use. Each subgroup is represented with a point estimate and confidence interval along a hazard ratio scale ranging from 0.0 to 2.0, with a vertical line at 1.0 indicating no effect.*
FDA Label Image

Carvedilol-figure3 (Carvedilol Figure3)

Carvedilol-figure3 (Carvedilol Figure3)
A line graph comparing mortality percentage over 24 months between Carvedilol and placebo groups. The x-axis shows time in months, and the y-axis shows percent mortality, with Carvedilol consistently lower than placebo. Statistical significance is indicated (P = 0.03).*
FDA Label Image

Figure-4 (Carvedilol Spl Figure 4)

Figure-4 (Carvedilol Spl Figure 4)
A forest plot chart displaying hazard ratios for various patient subgroups in a clinical study. The chart compares groups based on age, gender, timing post-myocardial infarction (MI), prior beta-blocker use, Killip classification, thrombolytic therapy, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (CHF) history, diuretic use during MI, angina, hypertension, diabetes, heart rate, and systolic blood pressure (SBP). Horizontal lines represent confidence intervals centered on hazard ratio points, with a vertical reference line at 1.0.*
FDA Label Image

Figure (Carvedilol 2)

Figure (Carvedilol 2)
A two-panel line graph showing changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of Carvedilol Phosphate extended-release capsules. It compares three dosages: 20 mg, 40 mg, and 80 mg. The time in hours is on the x-axis. Both SBP and DBP reduction trends are plotted for each dose with smoothed lines using locally weighted regression smoothing.*
FDA Label Image

Pdp-10mg (Carvedilol 3)

Pdp-10mg (Carvedilol 3)
Label for Carvedilol Phosphate Extended-Release Capsules 10 mg, oral extended-release capsules for once a day dosing. The package contains 30 capsules and is labeled for prescription use only. Manufactured by Northstar Rx LLC in Memphis, TN, and Frontida BioPharm, Inc. in Philadelphia, PA. The label includes usage instructions, storage temperature recommendations, and a barcode.*
FDA Label Image

Pdp-20mg (Carvedilol 4)

Pdp-20mg (Carvedilol 4)
Label for Carvedilol Phosphate Extended-Release Capsules, 20 mg strength. The label indicates oral capsule dosage form with once a day dosing. The package contains 30 capsules. Manufactured for NorthStar RxLLC, with additional manufacturing by Frontida BioPharm, Inc. The label includes a barcode and storage instructions.*
FDA Label Image

Pdp-40mg (Carvedilol 5)

Pdp-40mg (Carvedilol 5)
Packaging label for Carvedilol Phosphate Extended-Release Capsules, 40 mg strength, by NorthStar RxLLC. The label indicates the product is prescription only, with a dosage form of extended-release oral capsules. The package contains 30 capsules and instructs once-a-day dosing. The label includes storage instructions and manufacturer details, including Northstar Rx LLC and Prontida BioPharm, Inc.*
FDA Label Image

Pdp-80mg (Carvedilol 6)

Pdp-80mg (Carvedilol 6)
Carvedilol Phosphate Extended-Release Capsules 80 mg, oral dosage form in a pack containing 30 capsules. The label includes a dosage instruction of once a day dosing. Manufactured by NorthStar RxLLC with additional manufacturing by Frontida BioPharm, Inc. The label provides storage instructions and emphasizes keeping the medication out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.